AbbVie (ABBV) Stock Price, Fundamentals & Analysis

What ABBV does

AbbVie (ABBV) is a US-listed stock in the Healthcare sector, specifically in the Drug Manufacturers - General industry, headquartered in North Chicago, United States. The company is a research-based biopharmaceutical firm engaged in the research, development, manufacturing, and commercialization of medicines and therapies worldwide. Its portfolio includes treatments for autoimmune and inflammatory diseases (Skyrizi, Rinvoq), blood cancers (Imbruvica, Venclexta), various cancers (Elahere, Epkinly, Emrelis), and neurological conditions (Vraylar, Duodopa, Ubrelvy, Qulipta, Vyalev). AbbVie also offers aesthetic and skincare products such as Botox Cosmetic and Juvederm Collection. AbbVie is part of the S&P 500.

Key numbers explained

• Price and daily change: AbbVie trades at 265.08 USD, down -0.05% today.
• Market capitalization: 468.43B USD, reflecting its large-cap status.
• Valuation ratios: The trailing P/E ratio is 74.7, while the forward P/E ratio (based on expected earnings) is 16.3, suggesting a significant expected improvement in earnings relative to current levels.
• Earnings per share: Trailing 12-month EPS is 3.55 USD.
• Dividend: The dividend yield is 2.61%, with an ex-dividend date of Oct 15, 2026. Notably, the share of earnings paid out as dividends is 190%, indicating that current dividend payments exceed trailing earnings.
• Risk profile: The beta is 0.28, suggesting lower volatility relative to the broader market.
• Price range: The 52-week low and high are 190.75 and 269.39 respectively, with a 52-week price change of 20.6%.
• Financials: Trailing 12-month revenue is 64.39B USD, with a year-over-year revenue growth of 10.2%. The profit margin is 9.8%, while the operating margin is 40%.
• Next earnings: Expected on Oct 29, 2026.

Recent news

• Nvidia Backed This AI Drug Startup. AbbVie Just Became a Partner Before Its IPO
• What Is AbbVie No Longer Telling You?
• What Is The Best Case For Pfizer Stock?
• AbbVie (ABBV) Won EU Approval For RINVOQ In Pediatric Arthritis
• AbbVie (ABBV) Wins EU Approval for Rinvoq in Children. Why a Small Indication Still Matters
• AbbVie's Rinvoq Wins EU Approval in Juvenile Idiopathic Arthritis

What to watch

• Regulatory and clinical milestones: Monitor FDA and EMA decisions, trial readouts, and label expansions across AbbVie’s immunology, oncology, and neuroscience franchises, as these drive long-term revenue durability.
• Competitive dynamics: Track rival launches and pricing pressure in immunology and oncology, which can affect market share and margin trajectory.
• Pipeline execution: Watch for Phase 3 data and approvals that could broaden the portfolio and offset patent cliffs in key products.
• M&A and partnerships: Deals like the Nvidia-backed AI drug startup partnership may influence innovation pace and future growth options.
• Dividend sustainability: With a high payout ratio relative to trailing earnings, assess cash flow and balance sheet strength to gauge dividend resilience.